Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice
- Autores
- Funes, Samanta Celeste; Ríos, Mariana; Gómez Santander, Felipe; Fernández Fierro, Ayleen; Altamirano Lagos, María J.; Rivera Perez, Daniela; Pulgar Sepúlveda, Raul; Jara, Evelyn L.; Rebolledo Zelada, Diego; Villarroel, Alejandra; Roa, Juan C.; Mackern Oberti, Juan Pablo; Kalergis, Alexis M.
- Año de publicación
- 2019
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Current treatments for systemic autoimmune diseases partially improve the health of patients displaying low pharmacological efficacy and systemic immunosuppression. Here, the therapeutic potential of transferring tolerogenic dendritic cells (tolDCs) generated with heme-oxygenase inductor cobalt (III) protoporphyrin IX (CoPP), dexamethasone and rosiglitazone for the treatment of systemic autoimmunity was evaluated in two murine models of systemic lupus erythematosus (SLE), MRL-Faslpr and NZM2410 mice. Dendritic cells treated ex vivo with these drugs showed a stable tolerogenic profile after lipopolysaccharide stimulation. Regular doses of tolDCs were administered to anti-nuclear antibody-positive mice throughout 60–70 days, and the clinical score was evaluated. Long-term treatment with these tolDCs was well tolerated and effective to improve the clinical score on MRL-Faslpr lupus-prone mice. Additionally, decreased levels of anti-nuclear antibodies in NZM2410 mice were observed. Although tolDC treatment increased regulatory T cells, no significant reduction of renal damage or glomerulonephritis could be found. In conclusion, these results suggest that the transfer of histone-loaded tolDCs could improve only some SLE symptoms and reduced anti-nuclear antibodies. This is the first study to evaluate antigen-specific tolDC administration to treat SLE. Our report strengthens the clinical relevance of tolDC generation with CoPP, dexamethasone and rosiglitazone and the use of these modified cells as a therapy for systemic autoimmunity.
Fil: Funes, Samanta Celeste. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Ríos, Mariana. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Gómez Santander, Felipe. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Fernández Fierro, Ayleen. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile
Fil: Altamirano Lagos, María J.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Rivera Perez, Daniela. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Pulgar Sepúlveda, Raul. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile
Fil: Jara, Evelyn L.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Rebolledo Zelada, Diego. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Villarroel, Alejandra. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile
Fil: Roa, Juan C.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile
Fil: Mackern Oberti, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
Fil: Kalergis, Alexis M.. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile - Materia
-
AUTOIMMUNITY
HEME-OXYGENASE-1
SELF-TOLERANCE
SYSTEMIC LUPUS ERYTHEMATOSUS
TOLEROGENIC DENDRITIC CELLS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
.jpg)
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/219136
Ver los metadatos del registro completo
| id |
CONICETDig_9cf707d3c16976b6ac21cfe6e52273eb |
|---|---|
| oai_identifier_str |
oai:ri.conicet.gov.ar:11336/219136 |
| network_acronym_str |
CONICETDig |
| repository_id_str |
3498 |
| network_name_str |
CONICET Digital (CONICET) |
| spelling |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in miceFunes, Samanta CelesteRíos, MarianaGómez Santander, FelipeFernández Fierro, AyleenAltamirano Lagos, María J.Rivera Perez, DanielaPulgar Sepúlveda, RaulJara, Evelyn L.Rebolledo Zelada, DiegoVillarroel, AlejandraRoa, Juan C.Mackern Oberti, Juan PabloKalergis, Alexis M.AUTOIMMUNITYHEME-OXYGENASE-1SELF-TOLERANCESYSTEMIC LUPUS ERYTHEMATOSUSTOLEROGENIC DENDRITIC CELLShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Current treatments for systemic autoimmune diseases partially improve the health of patients displaying low pharmacological efficacy and systemic immunosuppression. Here, the therapeutic potential of transferring tolerogenic dendritic cells (tolDCs) generated with heme-oxygenase inductor cobalt (III) protoporphyrin IX (CoPP), dexamethasone and rosiglitazone for the treatment of systemic autoimmunity was evaluated in two murine models of systemic lupus erythematosus (SLE), MRL-Faslpr and NZM2410 mice. Dendritic cells treated ex vivo with these drugs showed a stable tolerogenic profile after lipopolysaccharide stimulation. Regular doses of tolDCs were administered to anti-nuclear antibody-positive mice throughout 60–70 days, and the clinical score was evaluated. Long-term treatment with these tolDCs was well tolerated and effective to improve the clinical score on MRL-Faslpr lupus-prone mice. Additionally, decreased levels of anti-nuclear antibodies in NZM2410 mice were observed. Although tolDC treatment increased regulatory T cells, no significant reduction of renal damage or glomerulonephritis could be found. In conclusion, these results suggest that the transfer of histone-loaded tolDCs could improve only some SLE symptoms and reduced anti-nuclear antibodies. This is the first study to evaluate antigen-specific tolDC administration to treat SLE. Our report strengthens the clinical relevance of tolDC generation with CoPP, dexamethasone and rosiglitazone and the use of these modified cells as a therapy for systemic autoimmunity.Fil: Funes, Samanta Celeste. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Ríos, Mariana. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Gómez Santander, Felipe. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Fernández Fierro, Ayleen. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; ChileFil: Altamirano Lagos, María J.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Rivera Perez, Daniela. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Pulgar Sepúlveda, Raul. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; ChileFil: Jara, Evelyn L.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Rebolledo Zelada, Diego. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Villarroel, Alejandra. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; ChileFil: Roa, Juan C.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; ChileFil: Mackern Oberti, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaFil: Kalergis, Alexis M.. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; ChileWiley Blackwell Publishing, Inc2019-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/219136Funes, Samanta Celeste; Ríos, Mariana; Gómez Santander, Felipe; Fernández Fierro, Ayleen; Altamirano Lagos, María J.; et al.; Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice; Wiley Blackwell Publishing, Inc; Immunology; 158; 4; 9-2019; 322-3390019-2805CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1111/imm.13119info:eu-repo/semantics/altIdentifier/doi/10.1111/imm.13119info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:02:32Zoai:ri.conicet.gov.ar:11336/219136instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:02:32.615CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
| dc.title.none.fl_str_mv |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| title |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| spellingShingle |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice Funes, Samanta Celeste AUTOIMMUNITY HEME-OXYGENASE-1 SELF-TOLERANCE SYSTEMIC LUPUS ERYTHEMATOSUS TOLEROGENIC DENDRITIC CELLS |
| title_short |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| title_full |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| title_fullStr |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| title_full_unstemmed |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| title_sort |
Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice |
| dc.creator.none.fl_str_mv |
Funes, Samanta Celeste Ríos, Mariana Gómez Santander, Felipe Fernández Fierro, Ayleen Altamirano Lagos, María J. Rivera Perez, Daniela Pulgar Sepúlveda, Raul Jara, Evelyn L. Rebolledo Zelada, Diego Villarroel, Alejandra Roa, Juan C. Mackern Oberti, Juan Pablo Kalergis, Alexis M. |
| author |
Funes, Samanta Celeste |
| author_facet |
Funes, Samanta Celeste Ríos, Mariana Gómez Santander, Felipe Fernández Fierro, Ayleen Altamirano Lagos, María J. Rivera Perez, Daniela Pulgar Sepúlveda, Raul Jara, Evelyn L. Rebolledo Zelada, Diego Villarroel, Alejandra Roa, Juan C. Mackern Oberti, Juan Pablo Kalergis, Alexis M. |
| author_role |
author |
| author2 |
Ríos, Mariana Gómez Santander, Felipe Fernández Fierro, Ayleen Altamirano Lagos, María J. Rivera Perez, Daniela Pulgar Sepúlveda, Raul Jara, Evelyn L. Rebolledo Zelada, Diego Villarroel, Alejandra Roa, Juan C. Mackern Oberti, Juan Pablo Kalergis, Alexis M. |
| author2_role |
author author author author author author author author author author author author |
| dc.subject.none.fl_str_mv |
AUTOIMMUNITY HEME-OXYGENASE-1 SELF-TOLERANCE SYSTEMIC LUPUS ERYTHEMATOSUS TOLEROGENIC DENDRITIC CELLS |
| topic |
AUTOIMMUNITY HEME-OXYGENASE-1 SELF-TOLERANCE SYSTEMIC LUPUS ERYTHEMATOSUS TOLEROGENIC DENDRITIC CELLS |
| purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| dc.description.none.fl_txt_mv |
Current treatments for systemic autoimmune diseases partially improve the health of patients displaying low pharmacological efficacy and systemic immunosuppression. Here, the therapeutic potential of transferring tolerogenic dendritic cells (tolDCs) generated with heme-oxygenase inductor cobalt (III) protoporphyrin IX (CoPP), dexamethasone and rosiglitazone for the treatment of systemic autoimmunity was evaluated in two murine models of systemic lupus erythematosus (SLE), MRL-Faslpr and NZM2410 mice. Dendritic cells treated ex vivo with these drugs showed a stable tolerogenic profile after lipopolysaccharide stimulation. Regular doses of tolDCs were administered to anti-nuclear antibody-positive mice throughout 60–70 days, and the clinical score was evaluated. Long-term treatment with these tolDCs was well tolerated and effective to improve the clinical score on MRL-Faslpr lupus-prone mice. Additionally, decreased levels of anti-nuclear antibodies in NZM2410 mice were observed. Although tolDC treatment increased regulatory T cells, no significant reduction of renal damage or glomerulonephritis could be found. In conclusion, these results suggest that the transfer of histone-loaded tolDCs could improve only some SLE symptoms and reduced anti-nuclear antibodies. This is the first study to evaluate antigen-specific tolDC administration to treat SLE. Our report strengthens the clinical relevance of tolDC generation with CoPP, dexamethasone and rosiglitazone and the use of these modified cells as a therapy for systemic autoimmunity. Fil: Funes, Samanta Celeste. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Ríos, Mariana. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Gómez Santander, Felipe. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Fernández Fierro, Ayleen. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile Fil: Altamirano Lagos, María J.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Rivera Perez, Daniela. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Pulgar Sepúlveda, Raul. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile Fil: Jara, Evelyn L.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Rebolledo Zelada, Diego. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Villarroel, Alejandra. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile Fil: Roa, Juan C.. Universidad Católica de Chile; Chile. Pontificia Universidad Católica de Chile; Chile Fil: Mackern Oberti, Juan Pablo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina Fil: Kalergis, Alexis M.. Pontificia Universidad Católica de Chile; Chile. Universidad Católica de Chile; Chile |
| description |
Current treatments for systemic autoimmune diseases partially improve the health of patients displaying low pharmacological efficacy and systemic immunosuppression. Here, the therapeutic potential of transferring tolerogenic dendritic cells (tolDCs) generated with heme-oxygenase inductor cobalt (III) protoporphyrin IX (CoPP), dexamethasone and rosiglitazone for the treatment of systemic autoimmunity was evaluated in two murine models of systemic lupus erythematosus (SLE), MRL-Faslpr and NZM2410 mice. Dendritic cells treated ex vivo with these drugs showed a stable tolerogenic profile after lipopolysaccharide stimulation. Regular doses of tolDCs were administered to anti-nuclear antibody-positive mice throughout 60–70 days, and the clinical score was evaluated. Long-term treatment with these tolDCs was well tolerated and effective to improve the clinical score on MRL-Faslpr lupus-prone mice. Additionally, decreased levels of anti-nuclear antibodies in NZM2410 mice were observed. Although tolDC treatment increased regulatory T cells, no significant reduction of renal damage or glomerulonephritis could be found. In conclusion, these results suggest that the transfer of histone-loaded tolDCs could improve only some SLE symptoms and reduced anti-nuclear antibodies. This is the first study to evaluate antigen-specific tolDC administration to treat SLE. Our report strengthens the clinical relevance of tolDC generation with CoPP, dexamethasone and rosiglitazone and the use of these modified cells as a therapy for systemic autoimmunity. |
| publishDate |
2019 |
| dc.date.none.fl_str_mv |
2019-09 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/219136 Funes, Samanta Celeste; Ríos, Mariana; Gómez Santander, Felipe; Fernández Fierro, Ayleen; Altamirano Lagos, María J.; et al.; Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice; Wiley Blackwell Publishing, Inc; Immunology; 158; 4; 9-2019; 322-339 0019-2805 CONICET Digital CONICET |
| url |
http://hdl.handle.net/11336/219136 |
| identifier_str_mv |
Funes, Samanta Celeste; Ríos, Mariana; Gómez Santander, Felipe; Fernández Fierro, Ayleen; Altamirano Lagos, María J.; et al.; Tolerogenic dendritic cell transfer ameliorates systemic lupus erythematosus in mice; Wiley Blackwell Publishing, Inc; Immunology; 158; 4; 9-2019; 322-339 0019-2805 CONICET Digital CONICET |
| dc.language.none.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/abs/10.1111/imm.13119 info:eu-repo/semantics/altIdentifier/doi/10.1111/imm.13119 |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| eu_rights_str_mv |
openAccess |
| rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
| dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
| publisher.none.fl_str_mv |
Wiley Blackwell Publishing, Inc |
| dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
| reponame_str |
CONICET Digital (CONICET) |
| collection |
CONICET Digital (CONICET) |
| instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
| repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
| _version_ |
1842980023375495168 |
| score |
12.993085 |